0001209191-18-046095.txt : 20180809
0001209191-18-046095.hdr.sgml : 20180809
20180809190432
ACCESSION NUMBER: 0001209191-18-046095
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180807
FILED AS OF DATE: 20180809
DATE AS OF CHANGE: 20180809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MacKenzie Lloyd
CENTRAL INDEX KEY: 0001600164
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36327
FILM NUMBER: 181006742
MAIL ADDRESS:
STREET 1: C/O AQUINOX PHARMACEUTICALS, INC.
STREET 2: 450 - 887 GREAT NORTHERN WAY
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC
CENTRAL INDEX KEY: 0001404644
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 887 GREAT NORTHERN WAY
STREET 2: SUITE 450
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
BUSINESS PHONE: 604-629-9223
MAIL ADDRESS:
STREET 1: 887 GREAT NORTHERN WAY
STREET 2: SUITE 450
CITY: VANCOUVER
STATE: A1
ZIP: V5T 4T5
FORMER COMPANY:
FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC
DATE OF NAME CHANGE: 20070626
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-08-07
0
0001404644
AQUINOX PHARMACEUTICALS, INC
AQXP
0001600164
MacKenzie Lloyd
C/O AQUINOX PHARMACEUTICALS, INC.
450 - 887 GREAT NORTHERN WAY
VANCOUVER
A1
V5T 4T5
BRITISH COLUMBIA, CANADA
0
1
0
0
Chief Operating Officer
Stock Option (Right to Buy)
3.07
2018-08-07
4
A
0
145000
0.00
A
2028-08-06
Common Stock
145000
145000
D
The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of August 7, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the Vesting Commencement Date.
/s/ Lloyd Mackenzie
2018-08-09